ibidi introduces angiogenesis assays in slide format

München, (PresseBox) - ibidi GmbH, a solutions supplier for bio-microscopy, has released a new carrier for angiogenesis assays, the µ-Slide Angiogenesis, during Analytica 2008.

Angiogenesis is one of the fastest growing research fields, as the formation of new blood vessels plays a crucial role in the developmental biology of embryos as well as in cancer research. The most established assays used to analyze new vessel formation in vitro are the 'tube formation and the 'sprouting assay . In both cases, the formation of new blood vessels is simulated on a gel matrix.

"We have developed a 'well-in-a-well structure, which drastically reduces the amount of matrix material and solves the classic meniscus problems. Via the miniaturized system of the inner well, the required amount of matrix is reduced to a value of 10 µl. The unique geometry of the slide places the cells that need to be imaged in the same focal plane, which strongly improves the imaging quality of the assays", says Roman Zantl, head of R&D at ibidi.

ibidi GmbH

ibidi® GmbH develops, produces and distributes micro-Slides (µ- Slides), a "Lab-on-a-Slide®" technology for the analysis of cells and biomolecules. The µ-Slides represent a new family of flow-through devices for the functional analysis of living cells and consisting of different slide types for cell-culture and high-end optical microscopy.

www.ibidi.com

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

So halten Unternehmen die Compliance mit Cognitive Computing ein

Der fol­gen­de Ar­ti­kel von Ste­fan Wel­cker, Ma­na­ging Di­rec­tor DACH, Ex­pert Sys­tem Deut­sch­land, er­läu­tert, warum Au­to­ma­ti­sie­rung im di­gi­ta­len Zei­tal­ter nur mit Cogni­ti­ve Com­pu­ting und Künst­li­cher In­tel­li­genz zu­ver­läs­sig funk­tio­nie­ren kann.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.